Maria Giovanna Marrosu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8298505/publications.pdf

Version: 2024-02-01

227 papers	7,693 citations	50170 46 h-index	82410 72 g-index
231 all docs	231 docs citations	231 times ranked	9384 citing authors

#	Article	IF	Citations
1	Deletion of the Dystrophin Muscle-Promoter Region Associated with X-Linked Dilated Cardiomyopathy. New England Journal of Medicine, 1993, 329, 921-925.	13.9	412
2	Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain, 2012, 135, 784-793.	3.7	182
3	Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis. Nature Genetics, 2010, 42, 495-497.	9.4	164
4	Age-related disability in multiple sclerosis. Annals of Neurology, 2002, 51, 475-480.	2.8	163
5	Population Based Study of 12 Autoimmune Diseases in Sardinia, Italy: Prevalence and Comorbidity. PLoS ONE, 2012, 7, e32487.	1.1	147
6	Prospective study of multiple sclerosis with early onset. Multiple Sclerosis Journal, 2002, 8, 115-118.	1.4	134
7	Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's disease. Journal of the Neurological Sciences, 2012, 323, 33-39.	0.3	132
8	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481.	2.8	118
9	Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study. Lancet, The, 2002, 359, 1461-1465.	6.3	112
10	Multiple Sclerosis in Sardinia Is Associated and in Linkage Disequilibrium with HLA-DR3 and -DR4 Alleles. American Journal of Human Genetics, 1997, 61, 454-457.	2.6	111
11	Large Proportion of Amyotrophic Lateral Sclerosis Cases in Sardinia Due to a Single Founder Mutation of the TARDBP Gene. Archives of Neurology, 2011, 68, 594.	4.9	104
12	The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. BMC Neurology, 2014, 14, 171.	0.8	99
13	Assessing response to interferon-Î² in a multicenter dataset of patients with MS. Neurology, 2016, 87, 134-140.	1.5	98
14	A genome screen for multiple sclerosis in Sardinian multiplex families. European Journal of Human Genetics, 2001, 9, 621-626.	1.4	95
15	Occurrence and clinical relevance of an interleukin-4 gene polymorphism in patients with multiple sclerosis. Journal of Neuroimmunology, 1997, 76, 189-192.	1.1	91
16	Multiple Sclerosis in Sardinia Is Associated and in Linkage Disequilibrium with HLAâ€ÐR3 and â€ÐR4 Alleles. American Journal of Human Genetics, 1997, 61, 454-457.	2.6	86
17	Association of Mycobacterium avium subsp. paratuberculosis with Multiple Sclerosis in Sardinian Patients. PLoS ONE, 2011, 6, e18482.	1.1	85
18	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurology, 2012, 12, 124.	0.8	82

#	Article	IF	Citations
19	Reversible Pisa syndrome in patients with Parkinsonâ€™s disease on dopaminergic therapy. Journal of Neurology, 2009, 256, 390-395.	1.8	81
20	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurology, 2012, 12, 165.	0.8	78
21	Communicating the diagnosis of multiple sclerosis - a qualitative study. Multiple Sclerosis Journal, 2007, 13, 763-769.	1.4	77
22	C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population. Neurobiology of Aging, 2012, 33, 1848.e15-1848.e20.	1.5	76
23	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain, 2015, 138, 3275-3286.	3.7	76
24	Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Multiple Sclerosis Journal, 2008, 14, 1225-1233.	1.4	72
25	Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis. Annals of Neurology, 2006, 59, 634-639.	2.8	69
26	Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia. Genes and Immunity, 2009, 10, 15-17.	2.2	69
27	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurological Sciences, 2009, 30, 193-199.	0.9	68
28	¹ H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e185.	3.1	68
29	Epidemiology of multiple sclerosis in south-western Sardinia. Multiple Sclerosis Journal, 2011, 17, 1282-1289.	1.4	66
30	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 845-850.	0.9	66
31	mtDNA nt13708A Variant Increases the Risk of Multiple Sclerosis. PLoS ONE, 2008, 3, e1530.	1.1	64
32	The inter-regional distribution of HLA class II haplotypes indicates the suitability of the Sardinian population for case-control association studies in complex diseases. Human Molecular Genetics, 2000, 9, 2959-2965.	1.4	62
33	The risk of Bipolar Disorders in Multiple Sclerosis. Journal of Affective Disorders, 2014, 155, 255-260.	2.0	61
34	Clinical assessment of gait in individuals with multiple sclerosis using wearable inertial sensors: Comparison with patient-based measure. Multiple Sclerosis and Related Disorders, 2016, 10, 187-191.	0.9	61
35	Genetic architecture of ALS in Sardinia. Neurobiology of Aging, 2014, 35, 2882.e7-2882.e12.	1.5	60
36	The Italian multiple sclerosis register. Neurological Sciences, 2019, 40, 155-165.	0.9	59

#	Article	IF	Citations
37	A Novel LIPE Nonsense Mutation Found Using Exome Sequencing in Siblings With Late-Onset Familial PartialÂLipodystrophy. Canadian Journal of Cardiology, 2014, 30, 1649-1654.	0.8	58
38	Treatment of early-onset multiple sclerosis with intramuscular interferonÎ²-1a: long-term results. Neurological Sciences, 2007, 28, 127-132.	0.9	57
39	ALS/FTD phenotype in two Sardinian families carrying bothC9ORF72andTARDBPmutations. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 730-733.	0.9	57
40	Effect of spasticity on kinematics of gait and muscular activation in people with Multiple Sclerosis. Journal of the Neurological Sciences, 2015, 358, 339-344.	0.3	57
41	Epsteinâ€“Barr virus and Mycobacterium avium subsp. paratuberculosis peptides are cross recognized by anti-myelin basic protein antibodies in multiple sclerosis patients. Journal of Neuroimmunology, 2014, 270, 51-55.	1.1	56
42	Familial cardiomyopathy, mental retardation and myopathy associated with desmin-type intermediate filaments. Neuromuscular Disorders, 1994, 4, 233-241.	0.3	55
43	Amyotrophic Lateral Sclerosisâ€“Frontotemporal Lobar Dementia in 3 Families With p.Ala382Thr TARDBP Mutations. Archives of Neurology, 2010, 67, 1002-9.	4.9	53
44	Clinical and molecular characterization of limbâ€girdle muscular dystrophy due to LAMA2 mutations. Muscle and Nerve, 2011, 44, 703-709.	1.0	52
45	Novel characterization of gait impairments in people with multiple sclerosis by means of the gait profile score. Journal of the Neurological Sciences, 2014, 345, 159-163.	0.3	52
46	Clinical phenotypes and radiological findings in frontotemporal dementia related to TARDBP mutations. Journal of Neurology, 2015, 262, 375-384.	1.8	50
47	Frontotemporal dementia with psychosis, parkinsonism, visuo-spatial dysfunction, upper motor neuron involvement associated to expansion of C9ORF72: a peculiar phenotype?. Journal of Neurology, 2012, 259, 1749-1751.	1.8	49
48	Analyzing Histopathological Features of Rare Charcot-Marie-Tooth Neuropathies to Unravel Their Pathogenesis. Archives of Neurology, 2010, 67, 1498-505.	4.9	48
49	What do multiple sclerosis patients and their caregivers perceive as unmet needs?. BMC Neurology, 2013, 13, 177.	0.8	48
50	Neuroactive steroid levels in plasma and cerebrospinal fluid of male multiple sclerosis patients. Journal of Neurochemistry, 2014, 130, 591-597.	2.1	48
51	Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis. Journal of Neuroimmunology, 2000, 105, 58-63.	1.1	46
52	Behavioral, neuropsychiatric and cognitive disorders in Parkinson's disease patients with and without motor complications. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1009-1013.	2.5	46
53	Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. Neurological Sciences, 2013, 34, 2085-2093.	0.9	46
54	Genome-Wide Association Study of Multiple Sclerosis Confirms a Novel Locus at 5p13.1. PLoS ONE, 2012, 7, e36140.	1.1	46

#	Article	IF	Citations
55	Muscle imaging analogies in a cohort of patients with different clinical phenotypes caused by LMNA gene mutations. Muscle and Nerve, 2010, 41, 458-463.	1.0	44
56	Rare and functional SIAE variants are not associated with autoimmune disease risk in up to 66,924 individuals of European ancestry. Nature Genetics, 2012, 44, 3-5.	9.4	44
57	Metabolomic analysis identifies altered metabolic pathways in Multiple Sclerosis. International Journal of Biochemistry and Cell Biology, 2017, 93, 148-155.	1.2	44
58	Hypersexual behaviour, frotteurism and delusional jealousy in a young parkinsonian patient during dopaminergic therapy with pergolide: A rare case of iatrogenic paraphilia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 1539-1541.	2.5	43
59	Structural and Dynamical Insights on HLA-DR2 Complexes That Confer Susceptibility to Multiple Sclerosis in Sardinia: A Molecular Dynamics Simulation Study. PLoS ONE, 2013, 8, e59711.	1.1	43
60	Epstein Barr Virus and Mycobacterium avium subsp. paratuberculosis peptides are recognized in sera and cerebrospinal fluid of MS patients. Scientific Reports, 2016, 6, 22401.	1.6	42
61	Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis. Functional Neurology, 2009, 24, 159-62.	1.3	42
62	Analysis of an IFN- gamma gene (IFNG) Polymorphism in Multiple Sclerosis in Europe: Effect of Population Structure on Association with Disease. Journal of Interferon and Cytokine Research, 1999, 19, 1037-1046.	0.5	41
63	The co-inheritance of type 1 diabetes and multiple sclerosis in Sardinia cannot be explained by genotype variation in the HLA region alone. Human Molecular Genetics, 2004, 13, 2919-2924.	1.4	41
64	Linkage disequilibrium analysis of chromosome 12q14â€“15 in multiple sclerosis: delineation of a 118-kb interval around interferon-Î³ (IFNG) that is involved in male versus female differential susceptibility. Genes and Immunity, 2002, 3, 470-476.	2.2	40
65	Multiple sclerosis and bipolar disorders: The burden of comorbidity and its consequences on quality of life. Journal of Affective Disorders, 2014, 167, 192-197.	2.0	40
66	Walking improvements with nabiximols in patients with multiple sclerosis. Journal of Neurology, 2015, 262, 2472-2477.	1.8	40
67	TBK1 is associated with ALS and ALS-FTD in Sardinian patients. Neurobiology of Aging, 2016, 43, 180.e1-180.e5.	1.5	40
68	Vagal nerve stimulation improves cerebellar tremor and dysphagia in multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 1200-1202.	1.4	39
69	Smoothness of gait detects early alterations of walking in persons with multiple sclerosis without disability. Gait and Posture, 2017, 58, 307-309.	0.6	39
70	Linkage analysis of multiple sclerosis with candidate region markers in Sardinian and Continental Italian families. European Journal of Human Genetics, 1999, 7, 377-385.	1.4	38
71	Othello Syndrome in Parkinson Disease Patients Without Dementia. Neurologist, 2009, 15, 34-36.	0.4	38
72	Vitamin D Responsive Elements within the HLA-DRB1 Promoter Region in Sardinian Multiple Sclerosis Associated Alleles. PLoS ONE, 2012, 7, e41678.	1.1	38

#	Article	IF	Citations
73	Bipolar affective disorder preceding frontotemporal dementia in a patient with C9ORF72 mutation: is there a genetic link between these two disorders?. Journal of Neurology, 2013, 260, 1155-1157.	1.8	38
74	The p.A382T TARDBP gene mutation in Sardinian patients affected by Parkinson's disease and other degenerative parkinsonisms. Neurogenetics, 2013, 14, 161-166.	0.7	38
75	Human interferon regulatory factor 5 homologous epitopes ofEpstein-Barrvirus andMycobacterium aviumsubsp.paratuberculosisinduce a specific humoral and cellular immune response in multiple sclerosis patients. Multiple Sclerosis Journal, 2015, 21, 984-995.	1.4	37
76	The current role of mitoxantrone in the treatment of multiple sclerosis. Expert Review of Neurotherapeutics, 2014, 14, 607-616.	1.4	36
77	A novel Cx32 mutation causes X-linked Charcot-Marie-Tooth disease with brainstem involvement and brain magnetic resonance spectroscopy abnormalities. Neurological Sciences, 2006, 27, 18-23.	0.9	35
78	Interferon-? gene polymorphism-associated risk for multiple sclerosis in sardinia. Annals of Neurology, 1998, 44, 841-842.	2.8	34
79	HLA-DRB1-DQB1 Haplotypes Confer Susceptibility and Resistance to Multiple Sclerosis in Sardinia. PLoS ONE, 2012, 7, e33972.	1.1	34
80	Heat shock protein 27 R127W mutation: evidence of a continuum between axonal Charcot-Marie-Tooth and distal hereditary motor neuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 958-962.	0.9	33
81	Overlapping syndromes in laminopathies: a meta-analysis of the reported literature. Acta Myologica, 2013, 32, 7-17.	1.5	33
82	Dilated cardiomyopathy with conduction defects in a patient with partial merosin deficiency due to mutations in the laminin€Î±2â€chain gene: A chance association or a novel phenotype?. Muscle and Nerve, 2011, 44, 826-828.	1.0	32
83	Influence of treatments in multiple sclerosis disability: A cohort study. Multiple Sclerosis Journal, 2015, 21, 433-441.	1.4	32
84	Aberrant sexual behaviours in Parkinsonâ€™s disease during dopaminergic treatment. Journal of Neurology, 2007, 254, 110-112.	1.8	31
85	Are Mycobacterium avium subsp. paratuberculosis and Epsteinâ€“Barr virus triggers of multiple sclerosis in Sardinia?. Multiple Sclerosis Journal, 2012, 18, 1181-1184.	1.4	31
86	Mycobacterium avium subsp. paratuberculosis and multiple sclerosis in Sardinian patients: epidemiology and clinical features. Multiple Sclerosis Journal, 2013, 19, 1437-1442.	1.4	31
87	A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. BMC Neurology, 2015, 15, 204.	0.8	31
88	Heterogeneity in the Magnitude of the Insulin Gene Effect on HLA Risk in Type 1 Diabetes. Diabetes, 2004, 53, 3286-3291.	0.3	30
89	Prevalence of primary blepharospasm in Sardinia, Italy: A service-based survey. Movement Disorders, 2006, 21, 2005-2008.	2.2	30
90	Levodopa/carbidopa/entacapone-induced acute Pisa syndrome in a Parkinsonâ€™s disease patient. Journal of the Neurological Sciences, 2008, 275, 154-156.	0.3	30

#	Article	IF	Citations
91	Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. Neurological Sciences, 2014, 35, 307-316.	0.9	30
92	Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. Neurological Sciences, 2017, 38, 1849-1858.	0.9	30
93	The impact of visible and invisible symptoms on employment status, work and social functioning in Multiple Sclerosis. Work, 2018, 60, 263-270.	0.6	30
94	Novel polymorphisms in the IL-10 related AK155 gene (chromosome 12q15). Genes and Immunity, 2001, 2, 284-286.	2.2	29
95	Allogeneic hematopoietic stem cell transplantation in a patient affected by large granular lymphocyte leukemia and multiple sclerosis. Annals of Hematology, 2004, 83, 403-405.	0.8	29
96	Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. Journal of Neuroimmunology, 2006, 179, 108-116.	1.1	29
97	Epitopes of HERV-Wenv induce antigen-specific humoral immunity in multiple sclerosis patients. Journal of Neuroimmunology, 2015, 280, 66-68.	1.1	29
98	Opposite Roles of NMDA Receptors in Relapsing and Primary Progressive Multiple Sclerosis. PLoS ONE, 2013, 8, e67357.	1.1	29
99	PECAM1, MPO and PRKAR1A at chromosome 17q21-q24 and susceptibility for multiple sclerosis in Sweden and Sardinia. Journal of Neuroimmunology, 2000, 108, 153-159.	1.1	28
100	Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: Importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients. Parkinsonism and Related Disorders, 2009, 15, 277-280.	1.1	28
101	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurology, 2014, 14, 114.	0.8	27
102	A cross-sectional and longitudinal study evaluating brain volumes, RNFL, and cognitive functions in MS patients and healthy controls. BMC Neurology, 2018, 18, 67.	0.8	27
103	Cognitive screening in patients with amyotrophic lateral sclerosis in early stages. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 95-101.	2.3	26
104	Antigenic epitopes of MAP2694 homologous to T-cell receptor gamma-chain are highly recognized in multiple sclerosis Sardinian patients. Molecular Immunology, 2014, 57, 138-140.	1.0	26
105	Are static and functional balance abilities related in individuals with Multiple Sclerosis?. Multiple Sclerosis and Related Disorders, 2017, 15, 1-6.	0.9	26
106	EBNA-1 IgG titers in Sardinian multiple sclerosis patients and controls. Journal of Neuroimmunology, 2013, 264, 120-122.	1.1	25
107	C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinsonâ€™s disease complicated by psychosis or dementia in a Sardinian population. Journal of Neurology, 2015, 262, 2498-2503.	1.8	25
108	The burden of multiple sclerosis and patientsâ€™ coping strategies. BMJ Supportive and Palliative Care, 2018, 8, 38-40.	0.8	25

#	Article	IF	Citations
109	Interaction between HLA-DRB1-DQB1 Haplotypes in Sardinian Multiple Sclerosis Population. PLoS ONE, 2013, 8, e59790.	1.1	25
110	Muscle MRI findings in patients with an apparently exclusive cardiac phenotype due to a novel LMNA gene mutation. Neuromuscular Disorders, 2008, 18, 291-298.	0.3	24
111	Anti Mycobacterium avium subsp. paratuberculosis heat shock protein 70 antibodies in the sera of Sardinian patients with multiple sclerosis. Journal of the Neurological Sciences, 2013, 335, 131-133.	0.3	24
112	Antigenic peptide molecular recognition by the DRB1â€“DQB1 haplotype modulates multiple sclerosis susceptibility. Molecular BioSystems, 2014, 10, 2043-2054.	2.9	24
113	Chromosome 7q21â€“22 and multiple sclerosis: evidence for a genetic susceptibility effect in vicinity to the protachykinin-1 gene. Journal of Neuroimmunology, 2002, 125, 141-148.	1.1	23
114	Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 975-980.	1.4	23
115	Dynamical insights into the differential characteristics of Mycobacterium avium subsp. paratuberculosis peptide binding to HLA-DRB1 proteins associated with multiple sclerosis. New Journal of Chemistry, 2015, 39, 1355-1366.	1.4	23
116	Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopaâ€“carbidopa intestinal gel infusion. Parkinsonism and Related Disorders, 2015, 21, 968-971.	1.1	23
117	PML in a person with multiple sclerosis. Neurology, 2018, 90, 83-85.	1.5	23
118	Role of Predisposing and Protective HLA-DQA and HLA-DQB Alleles in Sardinian Multiple Sclerosis. Archives of Neurology, 1993, 50, 256-260.	4.9	22
119	Effectiveness and Limitations of Unsupervised Home-Based Balance Rehabilitation with Nintendo Wii in People with Multiple Sclerosis. BioMed Research International, 2015, 2015, 1-8.	0.9	22
120	Multi-Platform Characterization of Cerebrospinal Fluid and Serum Metabolome of Patients Affected by Relapsingâ€“Remitting and Primary Progressive Multiple Sclerosis. Journal of Clinical Medicine, 2020, 9, 863.	1.0	22
121	Association of Mycobacterium avium subsp. paratuberculosis and SLC11A1 polymorphisms in Sardinian multiple sclerosis patients. Journal of Infection in Developing Countries, 2013, 7, 203-207.	0.5	22
122	Genetic loci linked to Type 1 Diabetes and Multiple Sclerosis families in Sardinia. BMC Medical Genetics, 2008, 9, 3.	2.1	21
123	Genetic and clinical characteristics of skeletal and cardiac muscle in patients with lamin A/C gene mutations. Muscle and Nerve, 2013, 48, 161-170.	1.0	21
124	Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?. Journal of Neurology, 2018, 265, 424-430.	1.8	21
125	Quantitative assessment of the effects of 6 months of adapted physical activity on gait in people with multiple sclerosis: a randomized controlled trial. Disability and Rehabilitation, 2018, 40, 144-151.	0.9	21
126	Italian consensus on treatment of spasticity in multiple sclerosis. European Journal of Neurology, 2020, 27, 445-453.	1.7	20

#	Article	IF	Citations
127	Surface markers on lymphocytes from human cerebrospinal fluid. Journal of Neuroimmunology, 1983, 5, 325-331.	1.1	19
128	Variable dystrophin expression in different muscles of a Duchenne muscular dystrophy carrier. Clinical Genetics, 1992, 42, 35-38.	1.0	19
129	Cardiac and muscle imaging findings in a family with X-linked Emeryâ€“Dreifuss muscular dystrophy. Neuromuscular Disorders, 2012, 22, 152-158.	0.3	19
130	Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up. Neurological Sciences, 2014, 35, 401-408.	0.9	19
131	Attitude towards physical activity in patients with multiple sclerosis: a cohort study. Neurological Sciences, 2015, 36, 889-893.	0.9	19
132	ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry. Neurobiology of Aging, 2015, 36, 2906.e1-2906.e5.	1.5	19
133	Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients. Scientific Reports, 2016, 6, 29268.	1.6	18
134	Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Groupâ€”Italian Neurological Society. Neurological Sciences, 2011, 32, 351-358.	0.9	17
135	Cardiac involvement in patients with lamin A/C gene mutations: A cohort observation. Muscle and Nerve, 2012, 46, 187-192.	1.0	17
136	Assessing the Metabolomic Profile of Multiple Sclerosis Patients Treated with Interferon Beta 1a by 1H-NMR Spectroscopy. Neurotherapeutics, 2019, 16, 797-807.	2.1	17
137	A genome-wide screen for linkage disequilibrium in Sardinian multiple sclerosis. Journal of Neuroimmunology, 2003, 143, 120-123.	1.1	16
138	The pharmacovigilance program on natalizumab in Italy: 2Âyears of experience. Neurological Sciences, 2009, 30, 163-165.	0.9	16
139	Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo®). Neuropsychiatric Disease and Treatment, 2010, 6, 483.	1.0	16
140	Fatigue, as measured using the Modified Fatigue Impact Scale, is a predictor of processing speed improvement induced by exercise in patients with multiple sclerosis: data from a randomized controlled trial. Journal of Neurology, 2018, 265, 1328-1333.	1.8	15
141	Is Geo-Environmental Exposure a Risk Factor for Multiple Sclerosis? A Population-Based Cross-Sectional Study in South-Western Sardinia. PLoS ONE, 2016, 11, e0163313.	1.1	15
142	Subacute Sclerosing Panencephalitis in Only One of Identical Twins. European Neurology, 1983, 22, 428-432.	0.6	14
143	ICAM-1 gene is not associated with multiple sclerosis in sardinian patients. Journal of Neurology, 2000, 247, 677-680.	1.8	14
144	Progressive multiple sclerosis and mood disorders. Neurological Sciences, 2015, 36, 1625-1631.	0.9	14

#	Article	IF	Citations
145	The heritage of glatiramer acetate and its use in multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	14
146	Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy. Neurological Sciences, 2016, 37, 613-622.	0.9	14
147	Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A caseâ€“control MRI study. Journal of Neurology, 2018, 265, 1096-1101.	1.8	14
148	Partial lipodystrophy associated with muscular dystrophy of unknown genetic origin. Muscle and Nerve, 2014, 49, 928-930.	1.0	13
149	Perception of risk and shared decision making process in multiple sclerosis. Expert Review of Neurotherapeutics, 2017, 17, 173-180.	1.4	13
150	PRF1 mutation alters immune system activation, inflammation, and risk of autoimmunity. Multiple Sclerosis Journal, 2021, 27, 1332-1340.	1.4	13
151	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Multiple Sclerosis Journal, 2022, 28, 472-479.	1.4	13
152	Tumor necrosis factor 2 allele does not contribute to increased tumor necrosis factor-? production in Sardinian multiple sclerosis. Annals of Neurology, 1999, 46, 799-800.	2.8	12
153	Refining the linkage analysis on chromosome 10 in 449 sib-pairs with multiple sclerosis. Journal of Neuroimmunology, 2003, 143, 31-38.	1.1	12
154	Interaction of loci within the HLA region influences multiple sclerosis course in the Sardinian population. Journal of Neurology, 2006, 253, 208-213.	1.8	12
155	The neuropeptide genes TAC1, TAC3, TAC4, VIP and PACAP(ADCYAP1), and susceptibility to multiple sclerosis. Journal of Neuroimmunology, 2007, 183, 208-213.	1.1	12
156	Dopamine Dysregulation Syndrome in Parkinson's Disease Patients on Duodenal Levodopa Infusion. Movement Disorders, 2013, 28, 840-841.	2.2	12
157	Role of interferon-beta in Mycobacterium avium subspecies paratuberculosis antibody response in Sardinian MS patients. Journal of the Neurological Sciences, 2015, 349, 249-250.	0.3	12
158	Lymphocyte subpopulations in blood and cerebrospinal fluid from patients with subacute sclerosing panencephalitis. Acta Neurologica Scandinavica, 1983, 67, 55-63.	1.0	11
159	PTPRC (CD45) C77G mutation does not contribute to multiple sclerosis susceptibility in Sardinian patients. Journal of Neurology, 2004, 251, 1085-8.	1.8	11
160	Dopaminergic-induced paraphilias associated with impulse control and related disorders in patients with Parkinson disease. Journal of Neurology, 2012, 259, 2752-2754.	1.8	11
161	C9<scp>ORF</scp>72 repeat expansion and bipolar disorder â€“ is there a link? No mutation detected in a Sardinian cohort of patients with bipolar disorder. Bipolar Disorders, 2014, 16, 667-668.	1.1	11
162	Charcotâ€“Marieâ€“Tooth disease: genetic subtypes in the Sardinian population. Neurological Sciences, 2017, 38, 1019-1025.	0.9	11

#	Article	IF	Citations
163	Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy. Multiple Sclerosis Journal, 2019, 25, 23-30.	1.4	11
164	Efficacy and Safety of Quetiapine Treatment for Delusional Parasitosis. Clinical Neuropharmacology, 2008, 31, 310-312.	0.2	10
165	A case of neurofibromatosis and multiple sclerosis. Neurological Sciences, 2010, 31, 631-634.	0.9	10
166	Aberrant splicing in the LMNA gene caused by a novel mutation on the polypyrimidine tract of intron 5. Muscle and Nerve, 2011, 43, 688-693.	1.0	10
167	Natalizumab in aggressive multiple sclerosis after haematopoietic stem cell transplantation. Neurological Sciences, 2012, 33, 863-867.	0.9	10
168	Fluctuations of MS births and UV-light exposure. Acta Neurologica Scandinavica, 2013, 127, 301-308.	1.0	10
169	Evaluation of the humoral response against mycobacterial peptides, homologous to MOG35â€“55, in multiple sclerosis patients. Journal of the Neurological Sciences, 2014, 347, 78-81.	0.3	10
170	Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. Therapeutics and Clinical Risk Management, 2015, 11, 759.	0.9	10
171	Constructional apraxia in frontotemporal dementia associated with the C9orf72 mutation: Broadening the clinical and neuropsychological phenotype. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 8-15.	1.1	10
172	The burden of multiple sclerosis variants in continental Italians and Sardinians. Multiple Sclerosis Journal, 2015, 21, 1385-1395.	1.4	10
173	Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs. Neurological Sciences, 2017, 38, 589-594.	0.9	10
174	Long-term follow-up more than 10Âyears after HSCT: a monocentric experience. Journal of Neurology, 2018, 265, 410-416.	1.8	10
175	Association between brain atrophy and cognitive motor interference in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 25, 208-211.	0.9	10
176	Surface Markers on Lymphocytes from Human Cerebrospinal Fluid. European Neurology, 1980, 19, 241-246.	0.6	9
177	Pulse steroid therapy in multiple sclerosis and mood changes: An exploratory prospective study. Multiple Sclerosis and Related Disorders, 2018, 20, 104-108.	0.9	9
178	Exploring cognitive motor interference in multiple sclerosis by the visual Stroop test. Multiple Sclerosis and Related Disorders, 2018, 22, 8-11.	0.9	9
179	Does focal inflammation have an impact on cognition in multiple sclerosis? An MRI study. Multiple Sclerosis and Related Disorders, 2018, 23, 83-87.	0.9	9
180	Cytokine production in patients carrying multiple sclerosis-linked HLA-DR alleles. Journal of Neurology, 1999, 246, 1194-1196.	1.8	8

#	Article	IF	Citations
181	A novel mutation in the central rod domain of lamin A/C producing a phenotype resembling the Emeryâ€“Dreifuss muscular dystrophy phenotype. Muscle and Nerve, 2007, 36, 828-832.	1.0	8
182	Relationship between gait initiation and disability in individuals affected by multiple sclerosis. Multiple Sclerosis and Related Disorders, 2015, 4, 594-597.	0.9	8
183	Soluble BAFF Level Is Not Correlated to Mycobacterium avium Subspecies Paratuberculosis Antibodies and Increases After Interferon-Î² Therapy in Multiple Sclerosis Patients. Journal of Molecular Neuroscience, 2016, 60, 91-93.	1.1	8
184	The contribution of HLA to multiple sclerosis susceptibility in Sardinian affected sibling pairs. Annals of Neurology, 2000, 47, 411-412.	2.8	7
185	Treatment of refractory chronic inflammatory demyelinating polyneuropathy with interferon Î²1B. Journal of Neurology, 2005, 252, 1420-1422.	1.8	7
186	Oxcarbazepine-Induced Leukopenia. Journal of Neuropsychiatry and Clinical Neurosciences, 2008, 20, 502-503.	0.9	7
187	Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances. Neurological Sciences, 2016, 37, 437-442.	0.9	7
188	A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1765-1788.	0.9	7
189	Toxic effect of intraventricular interferon-alpha in subacute sclerosing panencephalitis. Italian Journal of Neurological Sciences, 1994, 15, 153-155.	0.1	6
190	Lack of evidence for a role of the myelin basic protein gene in multiple sclerosis susceptibility in Sardinian patients. Journal of Neurology, 2002, 249, 1552-1555.	1.8	6
191	Variation of the Myelin Oligodendrocyte Glycoprotein gene is not primarily associated with multiple sclerosis in the Sardinian population. BMC Genetics, 2007, 8, 25.	2.7	6
192	Pathological gambling, delusional parasitosis and adipsia as a post-haemorrhagic syndrome: A case report. Neurocase, 2008, 14, 385-389.	0.2	6
193	Carpal tunnel syndrome triggered by excessive licorice consumption. Journal of the Peripheral Nervous System, 2009, 14, 64-65.	1.4	6
194	Multiple Spontaneous Cerebral Microbleeds and Leukoencephalopathy in PSEN1-Associated Familial Alzheimerâ€™s Disease: Mirror of Cerebral Amyloid Angiopathy?. Journal of Alzheimer's Disease, 2015, 47, 535-538.	1.2	6
195	A genetic association study of two genes linked to neurodegeneration in a Sardinian multiple sclerosis population: The TARDBP Ala382Thr mutation and C9orf72 expansion. Journal of the Neurological Sciences, 2015, 357, 229-234.	0.3	6
196	The Required Coefficient of Friction for evaluating gait alterations in people with Multiple Sclerosis during gait. Multiple Sclerosis and Related Disorders, 2016, 10, 174-178.	0.9	6
197	Phenotypic variability related to C9orf72 mutation in a large Sardinian kindred. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 245-248.	1.1	6
198	Quantifying gait impairment in individuals affected by Charcot-Marie-Tooth disease: the usefulness of gait profile score and gait variable score. Disability and Rehabilitation, 2020, 42, 737-742.	0.9	6

#	Article	IF	Citations
199	Medulloblastoma Induces unusual Headache with Clinical Picture of Basilar-Type Migraine Complicated by Ischaemic Infarcts. Cephalalgia, 2006, 26, 1238-1241.	1.8	5
200	An unusual infection in MS patient treated with dimethyl fumarate: A case report of omphalitis. Multiple Sclerosis and Related Disorders, 2016, 7, 65-67.	0.9	5
201	Cytokines and multiple sclerosis severity: No correlation among Sardinians. Annals of Neurology, 2000, 48, 816-816.	2.8	4
202	Subacute sclerosing panencephalitis in Italy. Acta Neurologica Scandinavica, 1986, 73, 160-167.	1.0	4
203	ParkinExon Rearrangements and Sequence Variants inLRRK2Mutations Carriers: Analysis on a Possible Modifier Effect onLRRK2Penetrance. Parkinson's Disease, 2010, 2010, 1-5.	0.6	4
204	Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis. Inflammation and Allergy: Drug Targets, 2014, 13, 134-143.	1.8	4
205	Cerebrospinal fluid lymphocyte subpopulations in multiple sclerosis. Italian Journal of Neurological Sciences, 1986, 7, 101-105.	0.1	3
206	Continuous Infusion of Apomorphine Improves Torsion Dystonia in a Boy Unresponsive to Other Dopaminergic Drugs. Journal of Child Neurology, 1996, 11, 343-345.	0.7	3
207	Lateral trunk flexion and Pisa syndrome in Parkinson's disease. Are they really always different conditions although denoting similar features?. Journal of Neurology, 2008, 255, 450-451.	1.8	3
208	Multiple sclerosis risk: interaction between human leukocyte antigen and the environment in Sardinian population. Multiple Sclerosis Journal, 2009, 15, 1030-1036.	1.4	3
209	Dopamine Dysregulation Syndrome in Parkinsonâ€™s Disease Patients with Unsatisfactory Switching from Immediate to Extended Release Pramipexole: A Further Clue to Incentive Sensitization Mechanisms?. Behavioural Neurology, 2013, 27, 563-566.	1.1	3
210	Localized pigmentation disorder after subcutaneous pegylated interferon beta-1a injection. Multiple Sclerosis Journal, 2018, 24, 231-233.	1.4	3
211	The impact of modifiable risk factors on lesion burden in patients with early multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 39, 101886.	0.9	3
212	Dopamine dysregulation syndrome in Parkinson's disease patients with unsatisfactory switching from immediate to extended release pramipexole: a further clue to incentive sensitization mechanisms?. Behavioural Neurology, 2013, 27, 563-6.	1.1	3
213	Subacute Sclerosing Panencephalitis and Hypoparathyroidism. European Neurology, 1985, 24, 149-152.	0.6	2
214	Transient unilateral spatial neglect during aura in a woman with sporadic hemiplegic migraine. Cephalalgia, 2013, 33, 1194-1197.	1.8	2
215	A Novel Mutation in Lamin A/C Gene: Phenotype and Consequences on the Protein Structure and Flexibility. SRX Biology, 2010, 2010, 1-7.	0.0	2
216	Polymerase Chain Reaction Analysis for Specific HTLV-1 Sequences from Cerebrospinal Fluid and Peripheral Blood Cells in Sardinian Multiple Sclerosis Patients. European Neurology, 1992, 32, 195-198.	0.6	1

#	Article	IF	Citations
217	Parental transmission of multiple sclerosis: Maternal, paternal, or neither?. Neurology, 2007, 69, 1202-1203.	1.5	1
218	Corrigendum to â€œLinkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeansâ€•[J. Neuroimmunol. 179 (2006) 108â€“116]. Journal of Neuroimmunology, 2007, 189, 175-176.	1.1	1
219	Susceptibility to multiple sclerosis: the role of interleukin genes. Lancet Neurology, The, 2007, 6, 846-847.	4.9	1
220	Ultrarapid mood cycling in a Parkinsonian patient: Is not always simply an â€œonâ€“offâ€•fluctuationâ€”A case report. Parkinsonism and Related Disorders, 2008, 14, 262-263.	1.1	1
221	Dopaminergic drugs, paraphilic fantasies, paraphilic behaviours and creativity in Parkinson's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 563-564.	2.5	1
222	Muscle <scp>MRI</scp> in female carriers of emerinopathy. European Journal of Neurology, 2013, 20, e127.	1.7	1
223	A genetic study of the FMR1 gene in a Sardinian multiple sclerosis population. Neurological Sciences, 2015, 36, 2213-2220.	0.9	1
224	Dopamine dysregulation syndrome in Parkinson's disease patients on levodopa-carbidopa intestinal gel. Parkinsonism and Related Disorders, 2015, 21, 1383-1384.	1.1	1
225	Progressive apraxia of speech in a patient with a C9orf72 mutation. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 608-609.	1.1	1
226	Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsingâ€“Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study). Frontiers in Neurology, 2021, 12, 637615.	1.1	1
227	Imbalance of CSF Lymphocyte Subsets in Multiple Sclerosis. , 1990, , 59-65.		1